<DOC>
	<DOCNO>NCT01750918</DOCNO>
	<brief_summary>This open-label , four-part Phase I/II study investigate safety , pharmacokinetics , pharmacodynamics clinical activity trametinib ( GSK1120212 ) dabrafenib ( GSK2118436 ) administer combination anti-EGFR antibody panitumumab subject BRAF-mutation V600E positive colorectal cancer ( CRC ) subject CRC secondary resistance prior anti-EGFR therapy . Part 1 study consist dose-escalation cohort , follow 3 + 3 enrollment scheme . Part 2 study consist expansion cohort investigate safety clinical activity dabrafenib combination panitumumab trametinib plus dabrafenib combination panitumumab . Part 3 study randomize Phase II study compare dose dabrafenib combination panitumumab trametinib plus dabrafenib combination panitumumab compare chemotherapy comparator ( regimen leucovorin calcium , fluorouracil , oxaliplatin ( FOLFOX ) , leucovorin calcium , fluorouracil , irinotecan hydrochloride ( FOLFIRI ) irinotecan without panitumumab bevacizumab ) . Subjects assign treatment group randomize fashion compare safety clinical activity . Part 4 study investigate trametinib/panitumumab combination , include dose escalation subsequent cohort expansion two patient population : 1 ) BRAF-mutation V600E positive CRC 2 ) subject CRC develop secondary resistance prior anti-EGFR therapy . The objective Part 4 identify recommend Phase 2 dose/regimen trametinib dose combination panitumumab dose escalation identify initial signal clinical activity expansion cohort .</brief_summary>
	<brief_title>BRAF/MEK/EGFR Inhibitor Combination Study Colorectal Cancer ( CRC )</brief_title>
	<detailed_description>This open-label , four-part Phase I/II study investigate safety , pharmacokinetics , pharmacodynamics clinical activity trametinib ( GSK1120212 ) dabrafenib ( GSK2118436 ) administer combination anti-EGFR antibody panitumumab subject BRAF-mutation V600E positive colorectal cancer ( CRC ) subject CRC secondary resistance prior anti-EGFR therapy . Part 1 study consist dose-escalation cohort , follow 3 + 3 enrollment scheme . Part 2 study consist expansion cohort investigate safety clinical activity dabrafenib combination panitumumab trametinib plus dabrafenib combination panitumumab . Part 3 study randomize Phase II study compare dose dabrafenib combination panitumumab trametinib plus dabrafenib combination panitumumab compare chemotherapy comparator ( regimen FOLFOX , FOLFIRI irinotecan without panitumumab bevacizumab ) . Subjects assign treatment group randomize fashion compare safety clinical activity . Part 4 study investigate trametinib/panitumumab combination , include dose escalation subsequent cohort expansion two patient population : 1 ) BRAF-mutation V600E positive CRC 2 ) subject CRC develop secondary resistance prior anti-EGFR therapy . The objective Part 4 identify recommend Phase 2 dose/regimen trametinib dose combination panitumumab dose escalation identify initial signal clinical activity expansion cohort .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subjects eligible enrolment study must meet follow criterion Provided write informed consent , Male female &gt; =18 year age able swallow retain orally administer study treatment clinically significant gastrointestinal ( GI ) abnormality may alter absorption malabsorption syndrome major resection stomach and/or bowel . Part 1 Part 2 : Histologically cytologicallyconfirmed diagnosis advance metastatic BRAF V600E mutation positive CRC Part 4A 4B ONLY : Histologically cytologicallyconfirmed diagnosis advance metastatic CRC either harbour BRAF V600E mutation , determine relevant genetic testing OR develop secondary resistance antiEGFR therapy , define patient derive benefit ( disease control base investigator assessment &gt; 6 month OR partial response [ confirm unconfirmed ] base RECIST 1.1 ) prior antiEGFRcontaining therapy ( define ) subsequently progress therapy . The antiEGFR therapy must recent therapy patient must progress base investigator assessment within 3 month screen . Acceptable prior antiEGFRcontaining therapy include : a. Monotherapy antiEGFR , include cetuximab panitumumab OR b. irinotecan/antiEGFR combo previously disease progression ( base investigator assessment ) irinotecancontaining regimen Part 3 : Histologically cytologicallyconfirmed diagnosis BRAFV600E mutation positive advance metastatic colorectal cancer ( CRC eligible receive fluoropyrimidinecontaining chemotherapy regimen experience documented radiographic progression one prior line fluoropyrimidinecontaining chemotherapy ( previous antiEGFR therapy exclude ) , Secondline advanced/metastatic disease , fail intolerant least one regimen fluoropyrimidinecontaining chemotherapy include irinotecan oxaliplatin advanced/metastatic setting . Enrollment Part 3 may occur follow confirmation KRAS wildtype cancer . Archival tissue require ; archival tissue available find contain tumor tissue , fresh biopsy require . Measurable disease per RECIST version 1.1 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . Men female partner childbearing potential must either prior vasectomy agree use one contraception method list protocol . Female subject eligible : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal female define 12 month spontaneous amenorrhea verify folliclestimulating hormone ( FSH ) level &gt; 40 Milliinternational unit per milliliter ( MIU/mL ) estradiol level &lt; 40 picogram per milliliter ( pg/mL ) . Childbearing potential agrees use one contraceptive method list protocol . Female subject must agree use contraception 7 day prior first dose study drug ( ) 6 month last dose panitumumab , 4 month last dose trametinib , 4 week last dose dabrafenib , whichever longer . Additionally , woman childbearing potential must negative serum pregnancy test within 7 day prior first dose study drug ( ) . Adequate organ system function define absolute neutrophil count great equal 1.2X10^9/Liter ( L ) , hemoglobin great equal 9 gram per deciliter ( g/dL ) 5.6 millimoles per litre ( mmol/L ) , platelet great equal 75 × 10^9/L , Prothrombin Time / International Normalized Ratio ( PT/INR ) Partial Thromboplastin Time ( PTT ) less equal 1.5X upper limit normal ( ULN ) ; serum magnesium great equal low limit normal ( LLN ) ; albumin great equal 2.5 g/dL 25 gram per liter ( g/L ) , total bilirubin less equal 1.5XULN , Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) less equal 2.5X ULN ; creatinine le equal 1.5XULN calculated creatinine clearance great equal 50mL/min ; leave ventricular ejection fraction ( LVEF ) great equal LLN echocardiography ( ECHO ) multigated acquisition scan ( MUGA ) . Subjects enrol France Italy : In France Italy , subject eligible inclusion study either affiliate , beneficiary , social security category . Subjects meet follow criterion must enrol study History prior malignancy , colorectal cancer . Any serious and/or unstable preexist medical , psychiatric disorder condition could interfere subject 's safety , obtain informed consent compliance study procedure . Current active liver biliary disease ( exception Gilbert 's syndrome asymptomatic gallstone , liver metastasis otherwise stable chronic liver disease per investigator 's assessment ) . History sensitivity heparin heparininduced thrombocytopenia . Currently receive cancer therapy ( chemotherapy , radiation therapy , immunotherapy biologic therapy ) . Prior exposure MEK inhibitor . Part 1 , Part 2 BRAFmutant patient Part 4 ONLY : Prior exposure BRAF inhibitor . Part 1 , Part 2 BRAFmutant patient Part 4 ONLY : Known presence KRASmutation base previous KRAStesting . Note : Propsective KRAS testing require . However , result previous KRAS test know , must use assess eligibility . KRAS test perform retrospectively patient . Part 3 : Prior exposure EGFR inhibitor antiEGFR antibody Received investigational approve anticancer drug within 4 week , within 5 halflives ( whichever short ) first dose study drug ( ) . At least 14 day must pass last dose prior investigational agent first dose study drug ( ) . Part 3 : Received one prior anticancer therapy metastatic setting , exclusive previous adjuvant regimen . Previous investigational anticancer therapy metastatic setting prohibit . Current use prohibit medication requirement dose medication treatment study drug ( ) . Known Hepatitis B , Hepatitis C infection . Any major surgery , radiotherapy immunotherapy within 4 week prior first dose study drug ( ) . Limited radiotherapy 2 week prior first dose study drug ( ) . Chemotherapy regimens delay toxicity within 3 week prior first dose study drug ( ) . Chemotherapy regimens give continuously weekly basis limit potential delayed toxicity within 2 week prior first dose study drug ( ) . Unresolved toxicity great National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) version 4 Grade 1 previous anticancer therapy , exception Grade 2 alopecia , Grade 2 neuropathy , laboratory value allow per inclusion criterion . History retinal vein occlusion ( RVO ) . Presence active gastrointestinal disease condition interfere significantly absorption , distribution , metabolism excretion drug . Previous colectomy acceptable . Subjects brain metastasis exclude , unless : All know lesion must previously treat surgery stereotactic radiosurgery , Brain lesion ( ) , present , must confirm stable ( i.e. , increase lesion size ) &gt; =90 day prior first dose study drug ( ) . This must document two consecutive MRI CT scan use contrast , Asymptomatic corticosteroid requirement &gt; =30 day prior first dose study drug ( ) , No enzymeinducing anticonvulsant &gt; =14 day prior first dose study drug ( ) . In addition , subject brain metastasis currently evidence disease ( NED ) , NED &gt; =12 week require must confirm two consecutive MRI CT scan ( use contrast ) separate &gt; =6 week , prior randomization . Enrollment subject brain metastasis meet criterion require approval GlaxoSmithKline ( GSK ) Medical Monitor . Psychological , familial , sociological geographical condition permit compliance protocol . History evidence cardiovascular risk include follow : LVEF &lt; LLN ; A QT interval correct heart rate use Bazett 's formula ( QTcB ; ) ≥ 480 millisecond ( msec ) ; .History evidence current clinically significant uncontrolled arrhythmia . Exception : Subjects control atrial fibrillation &gt; 30 day prior randomization eligible . History acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty , stenting within 6 month prior randomization . History evidence current &gt; = Class II congestive heart failure define New York Heart Association ( NYHA ) . Treatment refractory hypertension define blood pressure systolic &gt; 140 millimeter mercury ( mm Hg ) and/or diastolic &gt; 90 mm Hg control antihypertensive therapy ; Subjects intracardiac defibrillator permanent pacemaker ; Known cardiac metastasis Unstable pulmonary embolism , deep vein thrombosis , significant arterial/venous thromboembolic event &lt; =30 day randomization . If anticoagulation , subject must stable therapeutic dose prior randomization . Subjects history pneumonitis interstitial lung disease ( ILD ) . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study drug ( ) excipients . Pregnant lactate female . Unwillingness inability follow procedure outline protocol . Uncontrolled diabetes medical condition may interfere assessment toxicity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MEK inhibitor</keyword>
	<keyword>anti-EGFR antibody</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>BRAF inhibitor</keyword>
</DOC>